Delaware courts don’t normally look kindly on companies that try to pull out of merger agreements. Buyer’s remorse is for when you spend too much on a pair of shoes that hurt your feet—it’s not a reason to bail out on a multi-billion-dollar deal.

But this case was different. A team from Paul, Weiss, Rifkind, Wharton & Garrison won an unusual victory in the Court of Chancery on Monday, when Vice Chancellor J. Travis Laster (pictured above) ruled that German healthcare giant Fresenius SE & Co. could cancel its $4.75 billion agreement to acquire Illinois-based Akorn, Inc., a specialty generic pharmaceuticals company.